KDR and cancer: When administered along with chemotherapy, bevacizumab and small molecule receptor tyrosine kinase inhibitors directed against VEGFR-2 are of some benefit in several other cancers; however, although these therapies often prolong progression-free survival by a matter of months, they generally do not extend life [9].